Session 2: Proteomics and Metabolism of CLL

Co-Chair(s)

• 

  Catherine Wu, MD

  Professor of Medicine and Chief, Division of Stem Cell Transplantation and Cellular Therapies
  Dana-Farber Cancer Institute, Harvard Medical School
  Boston, MA, United States
• 

  Jennifer Abelin, PhD

  Senior Group Leader, Proteomics Group
  The Broad Institute
  Boston, MA, United States

Presentations:

• 10:35 AM – 10:50 AM EDT

  Influence of Metabolism of Leukemia Progression
  

  Speaker: Matthew Vander Heiden, MD, PhD – Massachusetts Institute of Technology
• 10:50 AM – 11:05 AM EDT

  Proteogenomic Characterization of CLL and Drug Response/Resistance
  

  Speaker: Sascha Dietrich, MD – University of Duesseldorf
• 11:05 AM – 11:20 AM EDT

  CLL Proteomics and Immunoproteomics
  

  Speaker: Catherine J. Wu, MD – Dana-Farber Cancer Institute, Harvard Medical School
• 11:20 AM – 11:30 AM EDT

  Targeting translation initiation as novel therapeutic in CLL
  

  Primary Author: Anne Largeot, PhD – Luxembourg Institute of Health

  Co-Author: Jerome Paggetti, PhD – Luxembourg Institute of Health

  Co-Author; Presenting Author: Etienne Moussay, PhD – Luxembourg Institute of Health
• 11:30 AM – 11:40 AM EDT

  METTL3 contributes to aggressive CLL via post-transcriptional regulation of splicing factor
  

  Primary Author: Yiming Wu, PhD – Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center

  Co-Author: Meiling Jin, PhD – Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center

  Co-Author: Mike Fernandez, BS – Department of Systems Biology, Beckman Research Institute of the City of Hope

  Co-Author: Stacey M. Fernandes, BS – Dana-Farber Cancer Institute

  Co-Author: Alexey V. Danilov, MD, PhD – Department of Hematology and Transplantation;
  City of Hope National Medical Center

  Co-Author: Jennifer R. Brown, MD, PhD – Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI); Department of Medicine, Harvard Medical School (HMS)

  Co-Author: Steven Rosen, MD – Department of Hematology& Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope Comprehensive Cancer Center

  Co-Author: Tanya Siddiqi, MD – City of Hope National Medical Center

  Co-Author; Presenting Author: Lili Wang, MD, PhD – Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia; Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope Comprehensive Cancer Center
• 11:40 AM – 11:50 AM EDT

  TRAF3 inactivation in chronic lymphocytic leukemia enhances metabolic cellular plasticity through metabolic reprogramming and associates with adverse prognosis
  

  Primary Author; Presenting Author: Claudia Pérez Carretero, PhD – University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca

  Co-Author: Miguel Quijada Álamo, PhD – University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca

  Co-Author: Mariana Tannoury, BSc – Sorbonne Université, Centre de Recherche des Cordeliers

  Co-Author: Léa Dehgane, BSc – Sorbonne Université, Centre de Recherche des Cordeliers

  Co-Author: Alberto Rodríguez Sánchez, BSc – Cancer Research Center, USAL

  Co-Author: David J Sanz, PhD – University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center

  Co-Author: Teresa González, PhD – University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca

  Co-Author: Rocío Benito Sánchez, PhD – University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca

  Co-Author: Elise Chapiro, MD, PhD – Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière

  Co-Author: Florence Nguyen-Khac, MD, PhD – Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière

  Co-Author: Ana E Rodríguez Vicente, PhD – University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca

  Co-Author: Santos A Susin, PhD – Sorbonne Université, Centre de Recherche des Cordeliers

  Co-Author: Jesús María Hernández Rivas, MD, PhD – University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain; Department of Hematology, University Hospital of Salamanca
• 11:50 AM – 12:05 PM EDT

  Panel Discussion With Interactivity and Audience Q&A